Cysteine Substitutions in Epidermal Growth Factor–Like Domains of Fibrillin-1: Distinct Effects on Biochemical and Clinical Phenotypes  by Schrijver, I. et al.
Am. J. Hum. Genet. 65:1007–1020, 1999
1007
Cysteine Substitutions in Epidermal Growth Factor–Like Domains of
Fibrillin-1: Distinct Effects on Biochemical and Clinical Phenotypes
I. Schrijver,1,* W. Liu,1,* T. Brenn,2 H. Furthmayr,2 and U. Francke1,3
1Howard Hughes Medical Institute and Departments of 2Pathology and 3Genetics, Stanford University School of Medicine, Stanford
Summary
Fibrillin-1 (FBN1) contains 47 epidermal growth factor
(EGF)–like domains characterized by six conserved cys-
teine residues. Cysteine substitutions that disrupt one of
the three disulfide bonds are frequent causes of Marfan
syndrome (MFS). We identified 19 new substitutions in-
volving cysteine residues in each of the six positions of
EGF-like domains. Allele-specific mRNA assays revealed
equal abundance of mutant and normal FBN1 tran-
scripts in all 10 individuals studied. Quantitative pulse-
chase analysis of fibrillin protein was performed on 25
mutant fibroblast strains with substitutions of 22 dif-
ferent cysteine residues in 18 different EGF-like domains
spanning the entire gene. Normal synthesis and stability
of mutant fibrillin molecules was seen in 20/25 individ-
uals, 11 of whom showed delayed intracellular pro-
cessing and/or secretion. In the remaining five cases, the
mutant protein was apparently unstable. In four of these
five cases, the second or third disulfide bond of EGF-
like domains immediately preceding an 8-cysteine or hy-
brid domain was affected. All but two mutations caused
severe reduction of matrix deposition, which was at-
tributed to a dominant-negative effect of mutant mol-
ecules. For genotype/phenotype comparisons, clinical
data on 25 probands and 19 mutation-positive family
members were analyzed. Ocular manifestations were
among the most consistent features (ectopia lentis in
86%, myopia in 80%). Nine mutations encoded by ex-
ons 26–32 resulted in early-onset classic MFS and, in
one case, neonatal-lethal MFS. Mutations outside this
region were associated with variable clinical phenotypes,
including individuals with fibrillinopathies not meeting
diagnostic criteria for MFS.
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Introduction
One of the most prevalent disorders of connective tissue,
Marfan syndrome (MFS [MIM 154700]) affects an es-
timated 1/5,000–10,000 individuals, without gender
bias or ethnic predisposition. The autosomal dominant
syndrome is characterized by a combination of cardio-
vascular, musculoskeletal, and ophthalmological fea-
tures, including aortic dilatation and dissection, doli-
chostenomelia, chest deformity, scoliosis, lens sublux-
ation, high myopia, and striae distensae (Pyeritz and
McKusick 1979). The criteria for the diagnosis of MFS
were recently revised, and it was proposed to include
the presence of a disease-causing mutation as a diag-
nostic criterion (de Paepe et al. 1996).
MFS is caused by mutations in the fibrillin-1 gene
(FBN1 [MIM 134757]) in band 15q21.1. The gene is
subdivided into 65 exons. The 9.7-kb transcript codes
for fibrillin-1, a 320-kD glycoprotein that is the primary
constituent of unique microfibrils in the connective-tis-
sue matrix of many organ systems (Sakai et al. 1986;
Corson et al. 1993; Pereira et al. 1993). Forty-seven
exons encode a complete epidermal growth factor
(EGF)–like protein domain, and 43 of these include the
consensus sequence for calcium binding Asp/Asn-x-Asp/
Asn-Glu/Gln-xm-Asp/Asn*-xn-Tyr/Phe, where “x” rep-
resents any amino acid, “*” indicates possible b-hy-
droxylation of this residue, and “m” and “n” can be
variable (Downing et al. 1996). Calcium plays a pivotal
role in conformational stability of the domain and con-
fers increased resistance to proteolytic degradation. In
addition, it may facilitate interdomain as well as inter-
molecular interactions (Kielty and Shuttleworth 1993;
Downing et al. 1996; Reinhardt et al. 1997a).
Each of the EGF-like domains contains six highly con-
served cysteine residues that form three disulfide
bridges—between C1 and C3, between C2 and C4, and
between C5 and C6—creating an antiparallel b-pleated
sheet conformation that enhances calcium binding
(Campbell and Bork 1993; Kielty and Shuttleworth
1993; Dietz and Pyeritz 1995; Reinhardt et al. 1997b).
Mutations in EGF-like domains in other genes encoding
extracellular proteins cause diseases—for example, those
of cholesterol regulation (Varret et al. 1998) and blood
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Table 1
Primers and Conditions to Assess Allele-Specific Transcript Levels for Seven Different Cysteine Substitutions
PRIMER PAIR
ANNEALING
TEMPERATURE
(C)
SIZE
(bp)
RESTRICTION
SITEb PROBANDDesignation
Sequencea
(5′r3′) Position
471 TATCCATCTCGGGAGCCACCA 1306 56 210 NciI ()c 9
2647 AATACACTCACCACCAGCC 1516
2543 TTACACGAGATGGGAAGGAC 1687 56 291 AvaII ()c 20
474 TGCTCCGCATGTGTGTGTCA 1978
2544 GTGAAACCCCTGGGATCTGC 1850 56 208 MaeII () 16
2545 GGCGCAACAGCATTCAGATT 2058
2549 GCTTGTGTTATGATGGATTC 3788 51 208 MaeII () 3
390 GTTGTGTGCTCCAATTTCA 3996
2550 GCAGGAAGCTTCAAATGTAG 4027 56 199 RsaI () 22
2551 GAGCACTCATCAAGGTCTGT 4226
2550 GCAGGAAGCTTCAAATGTAG 4027 56 199 RsaI () 23
2551 GAGCACTCATCAAGGTCTGT 4226
500 TTATACTCTAGCAGGGAATG 6468 49 215 MaeII () 15
2553 TATGACCCATAAGTGTTC 6683
a The base mismatch in each primer is underlined.
b () = Restriction created by mutation; (-) = restriction site abolished by mutation. The RsaI sites affected in
probands 22 and 23 are different from one another.
c Artificially created restriction site.
coagulation (Giannelli et al. 1998). In FBN1, 41/101
reported mutations affecting EGF-like domains replace
a cysteine residue (Pepe et al. 1997; Collod-Beroud et
al. 1998). On the basis of the limited clinical information
available, it appears that this class of mutation is typi-
cally associated with “classic MFS.” In our laboratory,
quantitative pulse-chase analysis of a few cysteine sub-
stitutions showed normal fibrillin synthesis and signifi-
cant reduction in extracellular-matrix deposition (Aoy-
ama et al. 1993, 1994).
During recent years, we have systematically searched
for FBN1 mutations in fibroblast-derived RNA and
DNA of individuals either diagnosed with or suspected
of having MFS. Several methods of mutation detection
were applied, including single-strand conformation anal-
ysis (SSCA) of overlapping reverse transcription–PCR
(RT-PCR) products (Tynan et al. 1993) and of amplified
exons (Hayward et al. 1997), heteroduplex analysis us-
ing mutation-detection enhancement (MDE) gels (Ni-
jbroek et al. 1995), long RT-PCR to detect exon skipping
(Liu et al. 1996), and denaturing high-performance liq-
uid chromatography (DHPLC) (Liu et al. 1998). In these
studies, we identified 170 unique FBN1 mutations, in-
cluding nucleotide substitutions, deletions, and inser-
tions; half of these were missense mutations.
To determine the range of molecular and clinical man-
ifestations, the present study focuses on 25 cysteine sub-
stitutions in EGF-like FBN1 domains. Of the 19 detected
in our laboratory, 6 had been reported elsewhere (Tynan
et al. 1993; Liu et al. 1998). We included six cysteine
substitutions identified elsewhere (Dietz et al. 1992a,
1992b; Kainulainen et al. 1994; Piersall et al. 1994). We
studied the effect of these mutations on fibrillin-1 tran-
script stability, as well as protein synthesis and secretion,
in cultured dermal fibroblasts. Results of quantitative
pulse-chase analysis were used to assign probands to one
of five groups based on fibrillin synthesis and extracel-
lular-matrix deposition (Aoyama et al. 1994). Reduced
fibrillin synthesis (50% of control value  2 SD, range
of 35%–70%) characterizes groups I and II, and a nor-
mal level of synthesis (100% of control value  2 SD)
defines groups III and IV. Deposition is proportionally
reduced (50% of control value 2 SD) in groups I and
III and is disproportionately low (!2 SD of control value)
in groups II and IV. Group V samples yield synthesis
and deposition values 170% of the control value and,
therefore, are considered to fall within the normal range
(Aoyama et al. 1994). In addition, the location of the
cysteine substitution, mutant mRNA levels, protein, and
clinical phenotypes were comparatively analyzed in pro-
bands and mutation-positive family members.
Subjects, Material, and Methods
Subjects and Samples
Informed consent, skin biopsies, and aortic-tissue
samples were obtained in accordance with a study pro-
tocol approved by the Stanford University Panel on Hu-
man Subjects in Medical Research. Probands and avail-
able family members were examined in the Center for
Marfan Syndrome and Related Connective Tissue Dis-
orders. Additional information was obtained from fam-
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ily- and medical-history questionnaires, medical records,
and phone interviews.
Fibroblast cultures were established for all probands.
Blood samples or buccal swabs (Cytobrush Plus Cell
Collector; Medscand Medical AB) were obtained from
probands and relatives. Genomic DNA and total RNA
were isolated from blood leukocytes or fibroblast cul-
tures, according to standard procedures. Buccal-swab
lysates were prepared as described elsewhere (Richards
et al. 1997) and were used directly in PCR.
Mutation Detection
For screening at the cDNA level, 22 PCR fragments
covering the FBN1 cDNA were amplified as reported
elsewhere (Tynan et al. 1993) and were analyzed by
SSCA with silver staining (Bio Rad) (Orita et al. 1989).
Genomic DNA was amplified with primers for individ-
ual FBN1 exons (Nijbroek et al. 1995; Liu et al. 1998).
Heteroduplexes were identified either by MDE (J. T.
Baker, Philipsburg, NJ) or by DHPLC, as described else-
where (Liu et al. 1998).
DNA Sequencing
PCR products displaying abnormal migration bands
during SSCA or heteroduplex analysis in MDE gels were
directly sequenced by the Sequenase PCR Product Se-
quencing Kit (United States Biochemical). All amplicons
with DHPLC peak profiles distinct from the homodu-
plex peaks of control samples, as well as some PCR
products with a heteroduplex band on MDE gels, were
purified with exonuclease and shrimp alkaline phospha-
tase, according to the manufacturer’s recommendations
(United States Biochemical), and were then sequenced
with fluorescent terminators on an ABI Prism 377 Se-
quencer (PE Biosystems).
Allele-Specific Expression Studies
To compare the transcripts of the mutant and normal
alleles, a PCR-RFLP method was devised for seven sam-
ples with cysteine substitutions. Because, in two cases,
the mutations did not abolish or create a restriction site,
artificial restriction sites were generated by PCR primers
that introduce a base substitution close to the codon of
interest (Haliassos et al. 1989; Lappalainen et al. 1995)
(table 1).
Reverse transcription (RT) was performed onDNaseI-
treated total RNA by means of Superscript II (Gibco
BRL Products), according to the protocol recommended
by PE Biosystems. RT products were denatured at 94C
for 9 min and then were PCR amplified for 20 cycles of
94C for 30 s, annealing at each primer set’s optimal
temperature (see table 1) for 30 s, and 72C for 30 s.
After that, one [32P]-dATP–labeled oligonucleotide of
each primer pair was added, and the reaction was con-
tinued for one more cycle, followed by a final extension
step of 72C for 10 min. The PCR products were di-
gested with the appropriate restriction enzymes (table 1)
and were loaded onto an 8% polyacrylamide gel, to
separate the two digested products. The signal intensities
on autoradiographs were determined by densitometry.
Five probands carrying cysteine substitutions were
heterozygous for the single-nucleotide polymorphism
(SNP) C8931T in the 3′ UTR (Maslen et al. 1991; Hew-
ett et al. 1994a) and/or T1875C in exon 15 (Hayward
et al. 1994). Allele-specific mRNA levels were studied
at the polymorphic sites by RT-PCR with published
primers for the 3′ UTR SNP. The exon 15 SNP was
amplified with the following RNA-specific primers: for-
ward, 5′-TGCAAAGACATTAACGAGTG-3′, bridging
exons 14 and 15; and reverse, 5′-CTCCGCATGTG-
TGTGTCAAC-3′, bridging exons 16 and 15—for 30
cycles, under the aforementioned conditions, at an an-
nealing temperature of 58C. The products of the two
alleles were distinguished by SSCA and silver staining,
according to the protocol provided by the manufacturer
(Bio Rad), and were subsequently quantified by scanning
densitometry.
Quantitative Pulse-Chase Analysis
According to a previously established protocol (Brenn
et al. 1996), primary fibroblast cultures from probands
and control individuals were grown to confluency and
were maintained for 10 d in Dulbecco’s modified eagle
medium (DMEM) with 15% FBS and antibiotics. Cells
were subsequently seeded at high density ( cells/55# 10
35-mm dish) and were maintained for 6 d. On day 7,
metabolic labeling was performed with 200 mCi of 35S-
L-cysteine (ICN) for 30min. Unincorporated isotopewas
removed by three washes with DMEM, and the newly
synthesized fibrillin was chased in DMEM for 8 and 20
h. The soluble cell-lysis fraction was collected after three
washes with DMEM and lysis with 700 ml of 50 mM
Tris-HCl, pH 8.0, containing a broad-spectrum protease
inhibitor (CompleteTM; Boehringer Mannheim) and
1%NP40. The insoluble fraction was collected after one
wash with the same NP40 buffer, by scraping the culture
dish with a rubber policeman and centrifugation at
13,000 g for 25 min at 4C. Trichloroacetic acid pre-
cipitation and SDS-PAGE were performed as described
elsewhere (Aoyama et al. 1993). The dried gels were
exposed to a phosphor screen and were visualized on a
phosphorimager (Molecular Dynamics). Labeled fibril-
lin-1 was identified and quantitated as described else-
where (Aoyama et al. 1994; Brenn et al. 1996). The
levels of FBN1 production and deposition, as insoluble
fibrillin, in the extracellular matrix were expressed as
percentages of control values obtained for normal con-
trol fibroblast cultures that were studied in parallel for
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Figure 1 Mutation detection in FBN1, by three different meth-
ods. Mutation screening of amplified FBN1 exons was conducted in
individuals with MFS. a, MDE heteroduplex analysis of individuals
P3, P20, P2, and P23 and a normal control (lanes N). Additional bands
are indicated by arrows. b, SSCA of individuals P16, P9, P15, P22,
P14, and P17 and of a normal control (lanes N). Migration position
of additional fragments is indicated by arrows. c, Altered elution pro-
files, by denaturing high-performance liquid chromatography of PCR
products of individuals P21 and P5 and of normal controls (N). On
sequencing of the PCR products with altered migration patterns or
DHLPC profiles, mutations leading to cysteine substitutionswere iden-
tified in each case.
each experiment. Assignments to biosynthetic groups
were made as before (Aoyama et al. 1994).
Results
Identification of Cysteine Substitutions
The different mutation-detection methods resulted in
the identification of 19 cysteine substitutions in EGF-
like FBN1 domains. SSCA of 22 overlapping RT-PCR
products yielded seven, heteroduplex analysis of all 65
amplified FBN1 exons by MDE gels revealed four, and
exon amplification and DHPLC detected eight (fig. 1).
Each of the abnormal fragment migration patterns and
DHPLC profiles was unique; the former were not seen
in 28 controls analyzed by SSCA or MDE, and the latter
were not present in 95 unrelated individuals with MFS
or related connective-tissue disorders who were studied
by DHPLC (Liu et al. 1998).
Regarding the type of substitution, in eight instances
arginine, in six tyrosine, in three phenylalanine, and in
one each serine and tryptophan replaced the cysteine
residue. The cysteine substitutions were distributed over
most of the FBN1 gene, from exon 11 to exon 64, which
encode the 6th–47th EGF-like domains (table 2). All
mutations but one, C476G in exon 11, were located in
EGF-like domains with consensus sequences for calcium
binding. All mutations were novel, except for C1242Y,
which elsewhere had been reported as C344Y by Kain-
ulainen et al. (1994). C1242Y was found as a de novo
occurrence in our patient and is only the 12th known
recurring mutation in the FBN1 gene (Collod-Beroud et
al. 1998).
Of the 19 cysteine substitutions identified, 13 repre-
sented de novo mutations in the probands, and 6 were
inherited. Pedigree analysis identified 35 individuals at
risk of carrying the mutation, and they were invited to
join the study. Blood samples or buccal swabs obtained
from 30 relatives of probands were genotyped by PCR
amplification and direct sequencing. Nineteen additional
mutation carriers were identified in five families.
Allele-Specific mRNA Levels
Allele-specific expression tests were developed for 10
representative mutant samples; in 7 of these cases the
tests were based on the specific mutation (fig. 2), and in
the 3 others they were based on heterozygosity for ex-
pressed SNPs. The mutations in these samples affect cys-
teine residues in each of the six positions of an EGF-like
domain ranging from the 3d to the 34th calcium-binding
domains (C1 [C1326R exon 32], C2 [C499R exon 12],
C3 [C2221R exon 54], C4 [C637R exon 15], C6
[C570R exon 13], C1361Y exon 32, and C1402W exon
33). The ratio of transcripts from the mutant and normal
alleles was virtually equal in all samples, regardless of
the positions of the substituted cysteines (fig. 2).
C1326R, C637R, and C832Y (C5, exon 20) were an-
alyzed for the C8931T SNP in the 3′ UTR (Maslen et
al. 1991; Hewett et al. 1994a) and revealed equal levels
of both allele-specific transcripts. C1086Y (C3, exon 26)
and C1672R (C4, exon 40) were informative for the 3′-
UTR SNP, as well as for the T1875C SNP in exon 15
(Hayward et al. 1994). Testing at both sites revealed
equal transcript levels (data not shown). Thus, in all of
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Table 2
Cysteine Substitutions in the FBN1 Gene, with Corresponding Biochemical Phenotypes, Grouped According to Replaced Cysteine within an
EGF-Like Domain
EFG-Like Domain
and FBN1 Exon
Nucleotide
Change
Amino Acid
Change
Fibrillin
Synthesis
(%)
Fibrillin
Deposition
(%)
Protein
Group Proband Reference(s)a
C1:
27 G3350A C1117Y 98 27 IVd 1 Aoyama et al. (1993), Tynan et al. (1993)
30 G3725A C1242Y 100 24 IV 2
30b G3725A C1242Y 73 20 IV 4 Kainulainen et al. (1994)
32 T3976C C1326R 122 27 IVd 3
49 T6049C C2017R 92 20 IVd 6 Liu et al. (1997, 1998)
64 G8057T C2686F 91 26 IVd 5 Liu et al. (1997, 1998)
C2:
12 T1495C C499R 81 20 IVd 9
25 G3116A C1039Y 116 23 IVd 8 Liu et al. (1997, 1998)
30b G3746C C1249S 116 27 IV 7 Dietz et al. (1992b), Aoyama et al. (1993)
C3:
26 G3257A C1086Y 98 18 IV 14
28 T3511C C1171R 119 26 IVd 10
40b T4987C C1663R 93 45 IIId 12 Dietz et al. (1992b), Aoyama et al. (1993)
54 T6661C C2221R 102 22 IV 15
54b G6662C C2221S 94 27 IVd 13 Dietz et al. (1992b), Aoyama et al. (1993)
56 G6920C C2307S 98 22 IVd 11 Dietz et al. (1992a), Aoyama et al. (1993)
C4:
15 T1909C C637R 38 11 II 16
40 T5014C C1672R 38 27 II 17
40 G5015T C1672F 75 28 IV 18
C5:
11b T1426G C476G 102 28 IV 19 Piersall et al. (1994)
20 G2495A V832Y 56 13 II 20 Liu et al. (1997, 1998)
C6:
13 T1708C C570R 50 28 II 21
31 T3958A C1320S 104 11 IV 22 Liu et al. (1997, 1998)
32 G4082A C1361Y 87 10 IVd 24
33 T4206G C1402W 81 15 IV 23
49 G6158T C2053F 58 44 I 25
a Mutations without reference(s) listed are reported here for the first time.
b Donated by another laboratory.
the 10 samples studied, mutant-gene transcription and
mutant-mRNA stability were apparently normal.
Fibrillin-Protein Studies
Fibroblasts from 25 individuals were studied by quan-
titative pulse-chase analysis; they included the 19 with
cysteine substitutions described here, the 1 reported in-
dividual with the recurrent C1242Y mutation (Kainu-
lainen et al. 1994), and 5 fibroblast strains that had been
analyzed elsewhere (Aoyama et al. 1993) (table 2). Eight
mutant-cell cultures were studied more than once, by
different researchers and at different passage levels. One
example (C2017R) is shown in figure 3. In comparison
with control fibroblasts, this mutation results in both
normal synthesis and a marked reduction in the amount
of insoluble fibrillin, a measure of matrix deposition of
newly synthesized fibrillin (Brenn et al. 1996). This type
of analysis yields four different patterns, depending on
the amount of synthesis and insoluble fibrillin (Aoyama
et al. 1994). The mutant-cell strain shown in figure 3
was also associated with a delay in intracellular trans-
port and/or secretion of fibrillin and was designated as
“group IVd.” Delayed secretion was observed in 11/20
cultures that generated apparently stable mutant protein
(groups III and IV) (table 2). All cysteine substitutions
except for two, designated as “group I” or “group IIId,”
caused severe reduction (i.e., !35% of control value) of
extracellular deposition of newly synthesized fibrillin
molecules.
To assess whether the position of the affected cysteine
within the EGF-like domain influences the protein phe-
notype, the 24 different substitutions were plotted onto
a model EGF-like domain, together with exon numbers
and corresponding protein phenotypes (fig. 4). Fibrillin
synthesis was within normal limits (for groups III and
IV) when residues C1, C2, and C3 of an EGF-like do-
main had been substituted by another amino acid. These
substitutions apparently did not affect stability of the
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Figure 2 Allele- specific RT-PCR products derived from the nor-
mal and mutated alleles of seven individuals with cysteine substitutions
(probands 9, 15, 3, 20, 23, 16, and 22), revealing equal biallelic
expression.
Figure 3 Abnormal deposition of labeled fibrillin (arrows), de-
tected by pulse-chase analysis of cultured dermal fibroblasts. Similar
amounts of fibrillin are found in the cytosol of normal control fibro-
blasts (lanes N) and in those of individual P6 (affected by mutation
C2017R), after a 30-min pulse with 35S-cysteine. A delay in intracel-
lular transport and/or secretion is indicated by the high amount of
fibrillin retained in the P6 cells after an 8-h chase period, compared
with that in a control (lanes N). The incorporation of pulse-labeled
fibrillin into the insoluble extracellular-matrix microfibrillar form is
severely reduced in the P6 cells, to ∼20% of that in normal control
fibroblasts, at 8 h and 20 h of chase. This result places P6 into protein
group IVd.
mutant protein during the 30-min pulse time. When res-
idues C4, C5, and C6 were replaced, fibrillin synthesis
was either normal or reduced to approximately one half,
the amount expected to represent the product of the
normal FBN1 allele (groups I and II).
To determine whether the specific EGF-like domain
or its location within the fibrillin monomer may have a
differential effect on the protein phenotype, we com-
pared data for several EGF-like domains in which more
than one cysteine had been substituted (fig. 4). In the
domain encoded by exon 30, two mutations affect cys-
teine residue C1, and one affects C2. The three fibroblast
cultures displayed the same biosynthetic profile defined
as group IV. In exon 40, a C3 substitutionwas associated
with protein group IIId, and two mutations affecting C4
had different consequences. Replacement of C4 by phe-
nylalanine resulted in a stable mutant protein (group IV),
whereas arginine substitution was associated with a
group II profile. Exons 54, 32, and 49 contained two
mutations each. Both mutations in exon 54 affected C3
and caused protein phenotype IV, yet only sub-
stitution by serine (C2221S)—and not by arginine
(C2221R)—was associated with delayed secretion. The
two mutations in exon 32, affecting C1 and C6, caused
delayed secretion as well (group IVd). The mutation in
exon 49, affecting C1, resulted in group IVd, but when
C6 was replaced, the protein was unstable and deposi-
tion was proportionately reduced (group I).
A potential positional effect was detected when we
were searching for explanations for biosynthetic groups
I and II, which were observed in five samples. The half-
normal amount of newly synthesized fibrillin protein in
the presence of normal amounts of mutant mRNA
pointed to rapid degradation of presumably misfolded
protein. Four of the mutants involved the EGF-like do-
mains encoded by exons 15, 20, 40, and 49, each of
which immediately precedes an 8-cysteine or hybrid do-
main (C637R, C832Y, C1672R, and C2053F, respec-
tively) (fig. 5). Whereas these mutations disrupt either
the C2-C4 or the C5-C6 disulfide bond, two others,
causing disruption of the C1-C3 bond and also located
in EGF-like domains on the amino-terminal side of 8-
cysteine domains (C2017R, in exon 49, and C2307S, in
exon 56), were associated with normal fibrillin produc-
tion but delayed intracellular transport/secretion of full-
length protein molecules (group IVd). Likewise, the IVd
protein phenotype was observed for a mutation that dis-
rupted the C2-C4 bond and that was located immedi-
ately adjacent to—but on the carboxy-terminal side
of—an 8-cysteine domain (C1039Y). An observed syn-
thesis level of 75% of the control value placed C1672F
into group IV, in apparent discrepancy with the place-
ment of C1672R in group II. This suggests that, in ad-
dition to position within the EGF domain and within
the fibrillin monomer, other factors—such as confor-
mational features due to substitutions—may influence
mutant-protein stability as well.
Clinical Phenotypes
Genotype/phenotype comparisons were performed for
44 individuals including 19 with newly identified cys-
teine mutations and their available affected family mem-
bers and six previously published cases (table 3). Al-
Schrijver et al.: Fibrillinopathies Due to Cysteine Mutations of FBN1 1013
Figure 4 Location of cysteine substitutions in a prototypical
EGF-like domain. Exon number (E), affected-codon number (C...X),
and biosynthetic groups (I, II, IIId, IV, and IVd; for explanation, see
text and the work of Aoyama et al. [1994, 1995]) are indicated for
25 individual substitutions of cysteine residues 1–6, denoted by black-
ened circles. Amino acids important for calcium binding are indicated
by cross-hatched or vertically striped circles.
though most of the study subjects met the revised
diagnostic criteria for MFS (de Paepe et al. 1996), there
were several notable exceptions (see below).
A highly consistent manifestation of cysteine substi-
tutions in EGF-like domains is ectopia lentis (EL). It was
documented by dilated-eye examination in 36/42 (86%)
of the individuals so examined. When the information
was available, lens dislocation was always bilateral.My-
opia, generally high grade, was also very common (33/
41 [80%]) and was often associated with retinal de-
tachment (9/39 [23%]). In the revised diagnostic criteria,
the term “myopia” has been replaced by “increased axial
length of the globe” (de Paepe et al. 1996); however,
ultrasonic axial length measurements were not available
for any of the patients studied. Since lengthening of the
globe leads to myopia, we have used medium- to high-
grade myopia in our patient evaluations. Other connec-
tive-tissue manifestations, such as pneumothorax (4/39
[10%]) and bilateral or recurrent inguinal hernias (3/40
[8%]), were less frequent.
With respect to the position of the replaced cysteine
residue within the EGF-like domain, the available data
suggested one possible correlation: scoliosis occurred
with higher frequency and severity, often requiring sur-
gical intervention, when the C1-C3 or C2-C4 disulfide
bonds were disrupted. For all other features, no clear
predilections were evident (table 3).
When clinical features were compared with respect to
the location of the affected exon within the FBN1 gene,
classic MFS was observed in association with mutations
in exons 11, 15, 27, 28, 30–33, 40, and 54. In general,
cysteine substitutions in exons 26–32 were associated
with aortic dilatation diagnosed in childhood and with
aortic-root replacement at age !30 years. Only one in-
dividual, patient 14 with a C3 substitution in exon 26,
had “neonatal MFS”; this individual died from cardi-
opulmonary failure a fewmonths after birth. Aortic-root
dilatation progressed slowly when the mutation was pre-
sent in exon 12 (family 9) or exon 20 (proband 19). In
the latter case, the proband’s child (19-01) has been
treated with b-blockers since age 3 years, which may
have contributed to slow progression. Family 5, with a
cysteine substitution in exon 64, had predominantly car-
diovascular involvement. On the other hand, the mu-
tation in exon 13 (proband 20) caused very few skeletal
features and no cardiac abnormalities. Serious cardio-
vascular involvement was also absent in the eight mem-
bers of family 6, whose ages were 2–69 years, and in
unrelated proband 25, all of whom carried a mutation
in exon 49. Although all of these nine individuals had
EL, thus far only one member of family 6 has been
diagnosed with a dilated aortic root. Not enough skeletal
system information was available to determine if this
individual (6-3) would meet current clinical criteria for
MFS. Possibly, none of the eight mutation-positivemem-
bers of this family have clinically defined MFS; neither
does proband 25.
The clinical data were also analyzed with respect to
protein group, on the basis of the assumption that in-
dividuals with the same mutation share biochemical
characteristics. There were 25 subjects in group IVd, 11
in group IV, 6 in group II, and 1 each in groups I and
IIId. Retinal detachment was reported in 9/31 individ-
uals in protein groups IV and IVd and in 0/8 individuals
in groups I, II, and IIId. In addition, all recurrent and/
or bilateral inguinal hernias were associated with groups
IV and IVd. The frequency of other features was not
obviously different.
Discussion
The first mutation of the FBN1 gene was identified in
1991, in two individuals with MFS (Dietz et al. 1991),
and many more have been reported since (Hayward and
Brock 1997; Pepe et al. 1997; Collod-Beroud et al.
1998); they include missense mutations, in-frame dele-
tions and insertions, splice-site mutations leading to
exon skipping, and nonsense or frameshift mutations
leading to premature-termination codons. Genotype-
phenotype correlations have been hampered by clinical
variability within and between families. The pronounced
interfamilial variability that is characteristic of MFS has
been attributed to the fact that most FBN1 mutations
are unique and family specific (Dietz and Pyeritz 1995).
Until now, significant genotype-phenotype associations
emerged only in cases of neonatal MFS. This severe,
early-lethal manifestation has been correlated with mu-
tations in exons 24–32; these exons encode the central
stretch of contiguous EGF-like domains (Milewicz and
Duvic 1994; Nijbroek et al. 1995; Liu et al. 1996;
Lonnqvist et al. 1996). Whereas it is possible that this
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Figure 5 Schematic representation of the fibrillin-1 domain structure and location of cysteine substitutions associated with groups I, II,
and IV, in relation to 8-cysteine or hybrid domains. Cysteine-residue mutations in boldface are associated with unstable mutant protein (group
II or group I [C2053F]), and those in italics are associated with stable mutant protein (group IV). Disruption of the disulfide bonds between
C2 and C4 or between C5 and C6, in an EGF-like domain immediately preceding either an 8-cysteine domain or a hybrid domain, appears to
predispose to protein degradation.
central region is important for alignment and stability
of the 10-nm microfibrils in the extracellular matrix
(Lonnqvist et al. 1996), the correlation of mutations in
this region with the neonatal MFS phenotype is not ab-
solute (Wang et al. 1997). Besides location, the type of
mutation also needs to be considered. Exon-skipping
mutations leading to in-frame deletion of one entire do-
main often cause neonatally lethal MFS (Liu et al. 1996),
whereas most missense mutations in this region do not
(Collod-Beroud et al. 1998; present study).
Mutations of FBN1 are associated not only with MFS
but also with a range of related phenotypes such as iso-
lated ascending-aortic ectasia, EL, or marfanoid body
habitus (Dietz and Pyeritz 1995). To separate MFS from
these and other connective-tissue diseases, clinical cri-
teria have been established and recently have been re-
vised (de Paepe et al. 1996). These criteria are quite
stringent and excludemany individuals and familieswith
isolated or systemic connective-tissue manifestations.
Since some of these individuals and families may still
carry mutations in FBN1, FBN2, or other genes and may
be at risk for potentially severe and life-threatening com-
plications, we have proposed an expanded concept,
called “fibrillinopathy,” to include all disorders associ-
ated with a mutation of either FBN1 or FBN2 (Aoyama
et al. 1995; Furthmayr and Francke 1997). A further
subclassification could emerge that is based on system-
atic analyses of molecularly defined subgroups. Type of
nucleotide change, type and stability of mutant mRNA,
and synthesis, processing, and secretion of mutant fi-
brillin monomers are some of the parameters that need
to be included in such studies, in order to assess molec-
ular and clinical pathological effects of FBN1mutations.
Here, we present the first such comprehensive analysis
of cysteine substitutions in EGF-like domains of FBN1.
This type of mutation is present in ∼25% of all patients
with MFS and, quite surprisingly, in others not meeting
MFS diagnostic criteria. Our study included 25 unre-
lated probands and 19 mutation-positive relatives. The
majority of these cysteine substitutions are novel and are
reported here for the first time.
Allele-specific mRNA levels were equal in all 10 sam-
ples that were selected to represent mutations affecting
each of the six cysteine residues in a distribution ranging
from the 3d to the 34th of the 43 calcium-binding EGF-
like domains. The finding of stable mutant transcripts
in all of the samples points to a mechanism of patho-
genesis in which the mutant fibrillin protein and its as-
sembly into microfibrils is central.
Cysteine substitutions disrupt one of three disulfide
bridges that covalently connect three pairs of cysteine
residues that are highly conserved in EGF-like domains
(Aoyama et al. 1993; Downing et al. 1996). This has a
predictable detrimental effect on the domain itself, as
shown in structural studies of similar domains in other
proteins, but it also perturbs calcium binding even when
the required consensus sequence is intact (Reinhardt et
al. 1997a). Calcium stabilizes the conformation of the
individual domain (Downing et al. 1996) and influences
packing of tandemly arranged EGF-like domains within
the same polypeptide chain, as well as the packing of
neighboring molecules that are thought to be precisely
aligned within the microfibril (Handford et al. 1990;
Rao et al. 1995; Reinhardt et al. 1997a). Thus, one
consequence could be that fibrillin structure is abnormal
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beyond the mutated domain, to include neighboring do-
mains as well.
To determine the effect that the different cysteine sub-
stitutions have on fibrillin-1 biosynthesis, processing,
and matrix deposition, quantitative pulse-chase analyses
were performed. The deposition of newly synthesized
fibrillin in the extracellular matrix of cultured fibroblasts
was severely reduced (!35%; groups II and IV [Aoyama
et al. 1994] in all but 2 of the 25 samples studied. In
earlier studies (Aoyama et al. 1995), assignment to these
two groups has been associated with early onset of as-
cending-aortic dilatation and earlier surgical interven-
tion, in comparison with individuals in groups I and III
(matrix deposition of 35%–70% of control value). The
consequences of the severely reduced deposition are
greater than expected and are attributable to a domi-
nant-negative effect of the mutant protein on the assem-
bly of fibrillin synthesized from the normal allele. The
quantitative pulse-chase technique is quite reliable. Con-
sistent results were obtained either with the same fibro-
blast strains maintained in our laboratory in repeated
experiments and from different passages or with fibro-
blasts carrying the same mutation that are from related
or unrelated individuals. Appropriately matched con-
trols are essential for quantitative analyses, since both
the age of the donor at the time of skin biopsy and the
passage number of the fibroblasts in culture clearly affect
fibrillin synthesis (authors’ unpublished data). For ex-
ample, relatively low levels of synthesis (73% of control
value) in proband 4, in comparison with that in the
unrelated proband 2 with the same C1242Y mutation,
is likely due to the advanced in vitro age of fibroblasts
with unknown passage level received from another lab-
oratory (Kainulainen et al. 1994).
Overall, fibrillin synthesis was within normal range
for the majority (20/25) of the mutations. The newly
synthesized fibrillin was apparently normal in size but
was retained intracellularly for a prolonged period in a
high proportion (11/20) of mutant samples. Presumably,
disruption of a disulfide bond causes the fibrillin mon-
omer to assume a protein conformation that delays in-
tracellular processing and/or secretion from the cell. Ki-
netic data indicate that this delay affects both the
products of the normal allele and those of the mutant
allele. This finding suggests that fibrillin monomers in-
teract with each other within cellular compartments. It
is currently unknown in which form fibrillin is trans-
ported/secreted and whether the postulated dominant-
negative effect on fibrillogenesis occurs intra- or extra-
cellularly. It also remains to be determined whether the
observed disruption of intracellular transport is linked
to intracellular degradation of the polypeptide chain.
The delayed-secretion phenotype did not correlate either
with the position of the mutated cysteine within the
EGF-like domain or with particular substituted amino
acids (fig. 4).
Fibrillin synthesis was consistently reduced in five mu-
tant samples (groups I and II). Allele-specific mRNA ex-
pression, however, was equal, excluding instability of the
mutant transcripts as the cause. The mutations affected
C4, C5, or C6 nonrandomly but not exclusively (fig. 4).
When the position of the affected EGF-like domain
within the molecule is taken into account (fig. 5), a pos-
sible correlation becomes apparent. In 4/5 group I or
group II samples, the disruption affected the C2-C4 or
C5-C6 disulfide bond in an EGF-like domain immedi-
ately preceding an 8-cysteine TGFb binding protein–like
or hybrid domain (C637R, C832Y, C1672F, and
C2053F). Degradation was not apparent either when the
C1-C3 bond was disrupted in such a domain (C2017R
and C2307S) or when the C2-C4 bond of the EGF-like
domain immediately following an 8-cysteine domain
was affected (C1039Y). However, secretion was delayed
(group IVd) in all three cases. This may suggest that the
folding of the 8-cysteine module critically depends on
proper formation of the C2-C4 and C5-C6 bonds in the
preceding EGF-like domain. If misfolded, the polypep-
tide chain may be particularly sensitive to proteolysis,
provided that sites for such an event are present (Rein-
hardt et al. 1997b). The finding that the C1672R mu-
tation generates a more stable mutant protein in com-
parison with the C1672F substitution could be related
to different conformations and/or protease sensitivities
of the mutant products; more-detailed studies are re-
quired for resolution of the underlying structural reason.
The putative truncated products of such selective cleav-
age are not detectable in our system but could be further
pursued with other methods of analysis (Reinhardt et
al. 1997b). Relatively stable proteolytic products might
exist in sufficient concentrations in the group II samples
because a group I phenotype would be expected if the
mutant monomers were completely degraded (Aoyama
et al. 1994).
The clinical phenotypes of our study group ranged
from severe manifestations of neonatal MFS in a single
individual to syndromes with relatively mild, mostly
skeletal findings (proband 6 and her seven affected rel-
atives and probands 19 and 25; table 3). The majority
of individuals with cysteine substitutions had classic
MFS and met diagnostic criteria on clinical grounds
alone. Clinical/molecular correlations were complicated
by a wide age range (2–73 years) in the individuals. In
the younger-age group, clinical phenotype and symp-
toms may not be fully developed; in others, earlymedical
intervention in relatives of patients either diagnosedwith
MFS or undergoing relevant cardiovascular surgical pro-
cedures may influence our clinical analyses, in two ways.
First, in such relatives at risk, the aortic-root diameter
will be more carefully monitored, which may lead to the
Table 3
Clinical Findings in Individuals with Cysteine Substitutions in EGF-Like Domains, at Age Listed
EXON SUBJECT (AGE)a
CLINICAL STATUSb
REFERENCEc
Skeletald Ophthalmologicale Cardiovascularf Otherg
DCS PE/PC SC H/NP DC CTR HSJ HLJ
Wrist
Sign
Thumb
Sign ARD Myopia EL RD
AAA
(Age
[years]) AD
ARR
(Age
[years]) MVP MR PMT Hernia Striae
Cysteine 1:
27 1 (30 years) h i        j  9  26     
30 2 (6 years)  k           j  8      l 
32 3 (7 years)  m             1  7     
30 4 (20 years)    j NAn  19  1
64 5 (27 years)  m               21     
5-2 (24 years)  o             26       
5-12 (160 years)  m              p   
5-01 (7 years)  m                    
49 6 (39 years)  m           j         
6-11 (69 years)          j       l 
6-02 (2 years)  h           j         
6-2 (40 years)            q j        r 
6-03 (12 years)  m           j         
6-3 (38 years)       j         
6-04 (6 years)              s 
6-05 (3 years)               
Cysteine 2:
30 7 (27 years)                   3
25 8 (30 years)        q     31  p   
12 9 (50 years)  m           j  50       
9-12 (73 years) m               65    t 
Cysteine 3:
28 10 (22 years)  k i         q j    22    l 
56 11 (53 years)  u p         2
40 12 (30 years)   i                3
54 13 (43 years)                  3
26 14 (2 mo)  h   NA               j 
54 15 (54 years)  h i         q j  47  47    j 
15-01 (27 years)  m          q j  18  24     
Cysteine 4:
15 16 (13 years)  h         j  13       
40 17 (38 years)  h             25  36    t 
17-2 (44 years)           q j  37  43     
18 (38 years)               14  35     
Cysteine 5:
11 19  m   j   4
20 20 (31 years)            q j  34       
20-01 (9 years)  m       q j  3       
Cysteine 6:
13 21 (24 years)  u           j         
31 22 (12 years)  u          q j    11     
33 23 (26 years)  m           j  25  25     
23-01 (5 years)            q j         
32 24 (28 years)             j  24  28     
24-11 (55 years)  m          j 36 54  
24-2 (25 years)  m       j  26       
24-02 (2 years)       
24-03 (8 years)  m          q j         
49 25 (28 years)             j         
a Probands are denoted by single numbers, and their relatives are denoted by hyphenated numbers; “-11” and “-12” denote the proband’s father and mother; “-1”–“-3” denote relatives in the
proband’s generation; and “-01”–“-05” represent offspring of individuals in the proband’s generation.
b A plus sign () denotes presence, a minus sign () denotes absence, a blank denotes that the status is unknown, and NA = not applicable.
c 1 = Kainulainen et al. (1994); 2 = Dietz et al. (1992a); 3 = Dietz et al. (1992b); 4 = Piersall et al. (1994).
d DCS = dolichostenomelia; PE/PC = pectus excavatum/pectus carinatum; SC = scoliosis; H/NP = high/narrow palate; DC = dental crowding; CTR = contractures; HSJ = hypermobile small joints;
HLJ = hypermobile large joints; ARD = arachnodactyly.
e EL = ectopia lentis; RD = retinal detachment.
f AAA = ascending-aortic aneurysm; AD = aortic dissection; ARR = aortic-root replacement; MVP = mitral-valve prolapse; MR = mitral regurgitation.
g PMT = pneumothorax.
h Pectus excavatum.
i Severe, requiring surgical correction.
j Bilateral.
k Pectus excavatum, severe.
l Unilateral.
m Pectus carinatum.
n Retinal aplasia.
o Pectus carinatum, severe.
p Severe.
q 14 diopters.
r Recurrent, bilateral.
s Umbilical.
t Incisional.
u Thoracic asymmetry.
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false impression that dilatation occurred at a younger
age. Second, preventive therapy with b-blockers in symp-
tomatic children of families with MFS is often initiated
at an early age and could substantially increase the in-
terval between diagnosis and aortic root–replacement
surgery. This delay in progression would be difficult to
separate from slow development of dilatation associated
with particular disease-causing mutations.
The most frequent distinctive features—arachno-
dactyly (88%), EL (86%), high/narrow palate (85%),
and hypermobile small joints (78%)—were equally fre-
quent in probands and secondarily ascertained relatives.
One of the major diagnostic criteria, EL, was also com-
mon (10/13 individuals) in previous case reports of cys-
teine substitutions in EGF-like domains (Hewett et al.
1994b; Dietz and Pyeritz 1995; Mathews et al. 1995;
Ades et al. 1996; Putnam et al. 1996; Booms et al. 1997;
Pepe et al. 1997). This high incidence of EL presumably
reflects the generally more severe nature of the disease
in the cysteine-substitution group. When these previous
reports are considered together with our data, the overall
frequency of EL (46/55 [84%]) is thus significantly
higher in individuals with this type of mutation, com-
pared with the estimated 60% frequency in all cases of
MFS (Maumenee 1981) and with the estimated 29%
frequency in all individuals with abnormal fibrillin bi-
osynthesis (Aoyama et al. 1995). These numbers imply
that the high frequency of EL associated with cysteine
substitutions in EGF-like domains predicts a frequency
of !60% for other types of FBN1 mutations. This pre-
diction is confirmed by the low incidence of EL in a
group with premature-termination mutations (authors’
unpublished data).
With respect to the possible effects that position of
the mutant EGF-like domain may have on the pheno-
type, mutations in exons 26–32 were associated with
earlier onset of ascending-aortic aneurysms. In our study
group, only 1/9 individuals with substitutions in this
region had a neonatal lethal form of the disease (Kain-
ulainen et al. 1994; Dietz and Pyeritz 1995), whereas
several others represented de novo mutations with di-
agnostic clinical manifestations early in life. This rather
severe phenotypic spectrum underscores the importance
of this central region of the molecule in the lateral align-
ment and stacking of fibrillin monomers (Liu et al.
1996).
Attempts to further correlate the frequency or severity
of other clinical manifestations with (1) involvement of
specific EGF-like domains, (2) cysteine residues within
domains, or (3) protein groups failed to yield significant
results. A larger sample size and more-sophisticated an-
alytical methods may detect such differences, if they in
fact exist. The common endpoint of pathogenic path-
ways for these mutations has been defined here by the
striking reduction of extracellular microfibrils, as deter-
mined by the pulse-chase assay. In most, if not all, of
these cases, a severe reduction of extracellular microfi-
brils can also be observed by immunofluorescence stud-
ies (Brenn et al. 1996). Deposition assessment by phos-
phorimaging of fibrillin bands on gels represents a more
reliable quantitative measure and can serve to differ-
entiate fibrillinopathies from other connective-tissue
disorders.
It is clear from our study that cysteine substitutions
in EGF-like domains play a major role in the pathogen-
esis of fibrillinopathies and that most of them are as-
sociated with classic MFS. Genotype-phenotype rela-
tionships—even in this selected group of individuals–are
complex, but our data will have additional value when
the molecular configuration of microfibrils and their in-
teractors become better understood. Results from mu-
tation-detection and biochemical studies of the fibrillin
protein will enhance diagnostic precision in the large
spectrum of fibrillinopathies and could eventually lead
to more-accurate prognostic predictions and treatment
of connective-tissue disorders, at an earlier age.
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